This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Seattle Genetics Closes Enrollment in Cervical Cancer Study
by Zacks Equity Research
Seattle Genetics (SGEN) and partner Genmab end enrollment in the phase II study on tisotumab vedotin for treating patients with advanced/metastatic cervical cancer.
The Zacks Analyst Blog Highlights: ANI, Kamada, Genomic Health and NewLink
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ANI, Kamada, Genomic Health and NewLink
4 Small Biotech Stocks Likely to Witness More Upside in 2019
by Zacks Equity Research
The biotech space is witnessing a rally so far in 2019. Here we discuss four stocks that are likely to witness a continuation of the uptrend going ahead.
Kamada (KMDA) Flat As Market Gains: What You Should Know
by Zacks Equity Research
Kamada (KMDA) closed at $5.79 in the latest trading session, marking no change from the prior day.
Blueprint Medicines Expediates Filings for Key Candidates
by Zacks Equity Research
Blueprint Medicines (BPMC) revs up the regulatory filling plans for its cancer candidates, avapritinib and BLU-667.
Zacks.com featured expert Kevin Matras highlights: Kamada, Plantronics, SkyWest, SYNNEX and Walker & Dunlop
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Kamada, Plantronics, SkyWest, SYNNEX and Walker & Dunlop
Agios (AGIO) Surges More Than 40% Year to Date: Here's Why
by Zacks Equity Research
Agios' (AGIO) first wholly owned precision medicine, Tibsovo, has been picking up the sales pace since its FDA approval last year with strong sequential growth delivered in Q4.
Agios Gains Breakthrough Therapy Status for Tibsovo Combo
by Zacks Equity Research
Agios (AGIO) receives a Breakthrough Therapy designation for Tibsovo combo to treat the newly diagnosed acute myeloid leukemia in adult patients with an IDH1 mutation.
Zacks.com featured expert Kevin Matras highlights: Kamada, Herc, Medifast, SkyWest and SP Plus
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Kamada, Herc, Medifast, SkyWest and SP Plus
Bet on These 5 Stocks With Rising Cash Flows for Higher Gains
by Zacks Equity Research
Looking beyond profits to a company's cash position will be far more rewarding as this highlights its true financial health.
Best 6 Bets With Sound Net Profit Margin to Lift Portfolio
by Zacks Equity Research
Let's take a look at six excellent stocks with handsome net profit margin that can build a winning portfolio.
Lexicon Falls as FDA Denies Approval to Type I Diabetes Drug
by Zacks Equity Research
FDA issues complete response letter for Lexicon Pharmaceuticals (LXRX) and partner Sanofi's marketing application for type I diabetes candidate, Zynquista.
Is Kamada (KMDA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (KMDA) Outperforming Other Medical Stocks This Year?
PhaseBio Stock Up on Positive Data From PB2452 Phase I Study
by Zacks Equity Research
PhaseBio's (PHAS) stock skyrockets on positive data from an early-stage study evaluating PB2452, showing immediate and sustained reduction in bleeding risk in patients taking AstraZeneca's Brilinta.
Lexicon Pharma Initiates Dosing in Biliary Tract Cancer Study
by Zacks Equity Research
Lexicon Pharma (LXRX) commences dosing of first patient in phase IIa study evaluating its marketed drug, Xermelo, in biliary tract cancer.
Zacks.com featured expert Kevin Matras highlights: Kamada, Plantronics, SkyWest, Middlefield and Walker & Dunlop
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Kamada, Plantronics, SkyWest, Middlefield and Walker & Dunlop
Scoop Up Big Gains With 5 Stocks Enjoying Rising Cash Flows
by Zacks Equity Research
Cash is the lifeblood of any business. It offers strength, vitality and flexibility to make investment decisions, and the fuel to run the growth engine.
Achillion (ACHN) Reports Narrower-Than-Expected Loss in Q4
by Zacks Equity Research
Achillion (ACHN) encourages with narrower-than-expected loss in Q4. However, the company did not generate any revenues in the period.
Grab These 6 Stocks That Boast Substantial Net Profit Margin
by Zacks Equity Research
Here are six stocks with spectacular net profit margin that can contribute to making a winning portfolio.
Merrimack (MACK) Incurs Narrower-Than-Expected Loss in Q4
by Zacks Equity Research
Merrimack's (MACK) loss betters estimates in Q4. However, the company fails to earn any revenues in the period.
Focus on 6 Top-Ranked Stocks With Solid Net Profit Margin
by Zacks Equity Research
Here are six marvelous stocks with significant net profit margin that investors can bank on for remarkable returns.
Is Kamada (KMDA) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Kamada (KMDA) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Kamada (KMDA) delivered earnings and revenue surprises of -350.00% and -42.37%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights: American River, BG Staffing, Evolution Petroleum, Kamada and Farmers & Merchants
by Zacks Equity Research
The Zacks Analyst Blog Highlights: American River, BG Staffing, Evolution Petroleum, Kamada and Farmers & Merchants
Dollar Strengthens on Turkey's Trouble: Top 5 Gainers
by Tirthankar Chakraborty
Lira loses more than 20% over the week as international markets react to the uncertainty over Turkey's capability to repay foreign-currency debts. Dollar hits a one-year high.